Knott David M Jr Has $3.97 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Knott David M Jr decreased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 228,000 shares of the company’s stock after selling 30,231 shares during the quarter. Travere Therapeutics makes up approximately 1.4% of Knott David M Jr’s portfolio, making the stock its 11th largest holding. Knott David M Jr owned 0.29% of Travere Therapeutics worth $3,972,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the company. Rhumbline Advisers boosted its position in shares of Travere Therapeutics by 2.2% in the fourth quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock valued at $2,112,000 after acquiring an additional 2,640 shares during the period. Arizona State Retirement System grew its position in Travere Therapeutics by 13.5% in the 4th quarter. Arizona State Retirement System now owns 22,396 shares of the company’s stock worth $390,000 after purchasing an additional 2,666 shares during the last quarter. R Squared Ltd bought a new position in shares of Travere Therapeutics during the 4th quarter worth about $53,000. Diversified Trust Co increased its holdings in shares of Travere Therapeutics by 27.5% during the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock worth $256,000 after purchasing an additional 3,169 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Travere Therapeutics by 20.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company’s stock valued at $279,000 after buying an additional 3,458 shares during the last quarter.

Analysts Set New Price Targets

TVTX has been the topic of several research reports. HC Wainwright boosted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. upped their target price on Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Citigroup increased their price objective on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Finally, Evercore ISI lifted their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Trading Down 8.9 %

TVTX stock opened at $17.92 on Tuesday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -4.37 and a beta of 0.75. The business has a fifty day moving average price of $20.75 and a 200 day moving average price of $18.57. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. Analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insider Activity

In other news, insider Jula Inrig sold 2,066 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the transaction, the insider now owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP William E. Rote sold 2,437 shares of Travere Therapeutics stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the sale, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 191,335 shares of company stock valued at $4,194,712 over the last three months. 3.75% of the stock is owned by insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.